The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Left or biventricular dysfunction/failure

Publications

Chang WT, Chen PW, Lin HW, Lin SH, Li YH

Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan.

ESC heart failure. 2021;8(6):5149-5158

Tanaka S, Ikari A, Nitta T, Horiuchi T

Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors.

Oxford medical case reports. 2017;2017(7):omx038

Ürun Y, Utkan G, Yalcin B, Akbulut H, Onur H, Oztuna DG, Şenler FC, Demirkazık A, İçli F

The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.

Experimental oncology. 2015;37(1):53-7

Maxwell CB, Jenkins AT

Drug-induced heart failure.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2011;68(19):1791-804

Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK

Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.

Mayo Clinic proceedings. 2008;83(2):197-203

Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(31):7820-6